Plasmid DNA expression systems for the purpose of immunization

Current Opinion in Biotechnology

Volumn 8, Issue 5, 1997, Pages 635-640

  Davis, Heather L ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DNA VACCINE; MONOCLONAL ANTIBODY; PLASMID DNA;

ADJUVANT THERAPY; ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CPG ISLAND; EXPRESSION VECTOR; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; INFECTION PREVENTION; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW;

EID: 0030700316     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(97)80041-9     Document Type: Article

References (61)

1. Conry RM, LoBuglio AF, Wright M, Sumerel L, Pike MJ, Johanning F, Benjamin R, Lu D, Curiel DT: Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 1995, 55:1397-1400.
2. Martinon F, Krishnan S, Lenzen G, Magné R, Gomard E, Guillet JG, Lévy JP, Meulien P: Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol 1993, 23:1719-1722.
3. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL: Direct gene transfer into mouse muscle in vivo. Science 1990, 247:1465-1468.
4. Tang D, DeVit M, Johnston SA: Genetic immunization is a simple method for eliciting an immune response. Nature 1992, 356:152-154.
5. Donnelly JJ, Ulmer JB, Liu MA: DNA vaccines. Life Sci 1997, 60:163-172.
6. Davis HL, Brazolot Millan CL: DNA-based immunization. In Blood Cell Biochemistry, vol 8: Hemopoiesis and Gene Therapy. Edited by Fairbairn LJ, Testa N. London: Plenum 1997, in press. This chapter provides a comprehensive overview of the DNA vaccine field to date, and includes a summary of all disease models that have been described.
7. Michel ML, Davis HL, Schleef M, Mancini M, Tiollais P, Whalen RG: DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci USA 1995, 92:5307-5311.
8. Donnelly JJ, Martinez D, Jansen KU, Ellis RW, Montgomery DL, Liu MA: Protection against papillomavirus with a polynucleotide vaccine. J Infect Dis 1996, 173:314-320.
9. Bueler H, Mulligan RC: Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1. Mol Med 1996, 2:545-555.
10. Chow YH, Huang WL, Chi WK, Chu YD, Tao MH: Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J Virol 1997, 71:169-178.
11. Geissler M, Gesien A, Tokushige K, Wands JR: Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol 1997, 158:1231-1237.
12. Hakim I, Levy S, Levy R: A nine-amino acid peptide from IL-1 beta augments antitumor immune responses induced by protein and DNA vaccines. J Immunol 1996, 157:5503-5511.
13. Iwasaki A, Stiernholm BJ, Chan AK, Berinstein NL, Barber BH: Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol 1997, 158:4591-4601.
14. Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon MA, Dang K, Wang B, Boyer JD, Weiner DB: In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997, 158:816-826.
15. Mahvi DM, Burkholder JK, Turner J, Culp J, Malter JS, Sondel PM, Yang NS: Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine. Hum Gene Ther 1996, 7:1535-1543.
16. Tsuji T, Hamajima K, Ishii N, Aoki I, Fukushima J, Xin KQ, Kawamoto S, Sasaki S, Matsunaga K, Ishigatsubo Y et al.: Immunomodulatory effects of a plasmid expressing B7-2 on human immunodeficiency virus-1-specific cell-mediated immunity induced by a plasmid encoding the viral antigen. Eur J Immunol 1997, 27:782-787.
17. Ridge JP, Fuchs EJ, Matzinger P: Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science 1996, 271:1723-1726.
18. Anderson ED, Mourich DV, Fahrenkrug SC, La Patra S, Shepherd J, Leong JA: Genetic immunization of rainbow trout (Oncorhynchus mykiss) against infectious hematopoietic necrosis virus. Mol Mar Biol Biotechnol 1996, 5:114-122.
19. Davis HL, McCluskie MJ, Gerin JL, Purcell RH: DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc Natl Acad Sci USA 1996, 93:7213-7218. This is the first demonstration of a DNA vaccine in chimpanzees, which are generally recognized to be most predictive of vaccine responses in humans owing to their very similar genetic make-up and, thus, immune systems.
20. Boyer JD, Ugen KE, Wang B, Agadjanyan M, Gilbert L, Bagarazzi ML, Chattergoon M, Frost P, Javadian A, Williams WV et al.: Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat Med 1997, 3:526-532. The results from this study using multivalent DNA vaccines in chimpanzees are very exciting in that they demonstrate protective efficacy against a heterologous strain of HIV.
21. Raz E, Carson DA, Parker SE, Parr TB, Abai AM, Aichinger G, Gromkowski SH, Singh M, Lew D, Yankauckas MA et al.: Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA 1994, 91:9519-9523.
22. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD Jr: DNA-based immunization by in vivo transaction of dendritic cells. Nat Med 1996, 2:1122-1128.
23. Haynes JR, McCabe DE, Swain WF, Widera G, Fuller JT: Particle-mediated nucleic acid immunization. J Biotechnol 1996, 44:37-42.
24. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL: DNA vaccines: protective immunizations by parental, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 1993, 90:11478-11482.
25. Keller ET, Burkholder JK, Shi F, Pugh TD, McCabe D, Malter JS, MacEwan EG, Yang NS, Ershler WB: In vivo particle-mediated cytokine gene transfer into canine oral mucosa and epidermis. Cancer Gene Ther 1996, 3:186-191.
26. Schubbert R, Renz D, Schmitz B, Doerfler W: Foreign (M13) DNA ingested by mice reaches peripheral leukocytes, spleen, and liver via the intestinal wall mucosa and can be covalently linked to mouse DNA. Proc Natl Acad Sci USA 1997, 94:961-966. The results of this paper provide hope that it may be possible to develop DNA vaccines that can be delivered by noninvasive means, and in particular by oral or respiratory routes. Such delivery could have high impact on vaccine delivery in the developing world and may allow induction of specific mucosal immunity.
27. Cox GJ, Zamb TJ, Babiuk LA: Bovine herpes virus 1: immune responses in mice and cattle injected with plasmid DNA. J Virol 1993, 67:1164-1168.
28. Davis HL, Brazolot Millan CL, Watkins SC: Immune-mediated destruction of transfected muscle fibers after direct gene transfer with antigen-expressing plasmid DNA. Gene Ther 1997,4:181-188.
29. Gray D, Kosco M, Stockinger B: Novel pathways of antigen presentation for the maintenance of memory, Int Immunol 1991, 3:141-148.
30. Ulmer JB, Deck RR, DeWitt CM, Donnelly JJ, Liu MA: Generation of MHC class-I restricted T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology 1996, 89:59-67. Although it did not completely answer the question, this is the first paper to shed light on the possible mechanism of antigen presentation with DNA vaccines.
31. Corr M, Lee DJ, Carson DA, Tighe H: Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med 1996, 184:1555-1560.
32. Doe B, Selby M, Barnett S, Baenziger J, Walker CM: Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc Natl Acad Sci USA 1996, 93:8578-8583.
33. Manickan E, Karem KL, Rouse BT: Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. J Leukoc Biol 1997, 61:125-132.
34. Davis HL, Mancini M, Michel ML, Whalen RG: DMA-mediated immunization to hepatitis B surface antigen: longevity of primary response and effect of boost Vaccine 1996, 14:910-915.
35. Raz E, Tighe H, Sato Y, Corr M, Dudler JA, Roman M, Swain SL, Spiegelberg HL, Carson DA: Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 1996, 93:5141-5145. This paper is important in that it evokes the possibility of using DNA vaccines for the immunotherapeutic treatment of asthma, through redirection of a Th2 to a Th1 response.
36. Barry MA, Johnston SA: Biological features of genetic immunization. Vaccine 1997, 15:in press.
37. Lewis JG, Lin KY, Kothavale A, Flanagan WM, Matteucci MD, DePrince RB, Mook RA Jr, Hendren RW, Wagner RW: A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc Natl Acad Sci USA 1996, 93:3176-3181.
38. Feltquate DM, Heaney S, Webster RG, Robinson HL: Different T helper cell types and antibody isotopes generated by saline and gene gun DNA immunization. J Immunol 1997, 158:2278-2284.
39. Pertmer TM, Roberts TR, Haynes JR: Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol 1996, 70:6119-6125.
40. Torres CA, Iwasaki A, Barber BH, Robinson HL: Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J Immunol 1997, 158:4529-4532.
41. Klinman DM, Yi AK, Beaucage SL, Conover J, Kreig AM: CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996, 93:2879-2883.
42. Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, Silverman GJ, Lotz M, Carson DA, Raz E: Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996, 273:352-354. This paper is the first to show that CpG-containing immunostimulatory motifs are essential for the efficacy of DNA vaccines.
43. Klinman DM, Yamshchikov G, Ishigatsubo Y: Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 1997, 158:3635-3639.
44. Krieg AM, Yi AK, Schorr J, Davis HL: The role of CpG dinucleotides in DNA vaccines. Trends Immunol 1997, in press.
45. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374:546-549.
46. Ballas ZK, Rasmussen WL, Krieg AM: Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996, 157:1840-1845.
47. Cowdery JS, Chace JH, Yi AK, Krieg AM: Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol 1996, 156:4570-4575.
48. Ertl HC, Xiang ZQ: Genetic immunization. Viral Immunol 1996, 9:65-71.
49. Bot A, Antohi S, Bona CA: Immune response of neonates elicited by somatic transgene vaccination with naked DNA. Front Biosci 1997, 2:173-188.
50. Wang Y, Ziang Z, Pasquini S, Ertl HCJ: Immune response to a neonatal genetic immunization. Virology 1997, 228:278-284. This is the first paper to describe successful immunization of neonates with DNA vaccines.
51. Mancini M, Hadchouel M, Davis HL, Whalen RG, Tiollais P, Michel ML: DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci USA 1996, 93:12496-12501. This paper shows the potential of DNA vaccines for immunotherapeutic treatment of chronic viral infections. In this case, a DNA vaccine was able to break tolerance in a transgenic mouse model of the hepatitis B chronic carrier and to down regulate viral gene expression in the liver through a noncytolytic mechanism.
52. Conry RM, LoBuglio AF, Curiel DT: Polynucleotide-mediated immunization therapy of cancer. Semin Oncol 1996, 23:135-147.
53. Conry RM, LoBuglio AF, Loechel F, Moore SE, Sumerel LA, Barlow DL, Curiel DT: A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther 1995, 2:59-65.
54. Conry RM, LoBuglio AF, Loechel F, Moore SE, Sumerel LA, Barlow DL, Pike J, Curiel DT: A carcinoembryonic antigen polynucleotide vaccine for human clinical use. Cancer Gene Ther 1995, 2:33-38.
55. Schirmbeck R, Bohm W, Reimann J: DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors. J Immunol 1996, 157:3550-3558.
56. Irvine KR, Rao JB, Rosenberg SA, Restifo NP: Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 1996, 156:238-245.
57. Rakhmilevich AL, Turner J, Ford MJ, McCabe D, Sun WH, Sondel PM, Grota K, Yang NS: Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 1996, 93:6291-6296.
58. Ciernik IF, Berzofsky JA, Carbone DP: Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J Immunol 1996, 156:2369-2375. This is a novel approach to immunization which is really only possible with the DNA vaccine approach - namely immunization with short peptides representing single T-cell epitopes. With antigen-based approaches, such short peptides are too unstable and thus they have to be covalently linked to some other molecule.
59. Barry MA, Lai WC, Johnston SA: Protection against mycoplasma infection using expression-library immunization. Nature 1995, 377:632-635.
60. Lai WC, Bennett M, Johnston SA, Barry MA, Pakes SP: Protection against Mycoplasma pulmonis infection by genetic vaccination. DNA Cell Biol 1995,14:643-651.
61. Ulmer JB, Lui MA: ELI's coming: expression library immunization and vaccine antigen discovery. Trends Microbiol 1996, 4:169-170.